Acrivon Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $70.71M
- P/E (TTM)
- –
- Dividend yield
- –
About Acrivon Therapeutics
Pharmaceutical Preparations, SIC 2834
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology medicines. The company utilizes its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics (AP3) platform to quantify drug-regulated pathway activity levels inside intact tumor cells in an unbiased manner. Its core pipeline includes ACR-368 (prexasertib), a targeted CHK1 and CHK2 inhibitor undergoing Phase 2b clinical trials for indications such as endometrial cancer, and ACR-2316, a selective dual WEE1/PKMYT1 inhibitor in Phase 1 evaluation. In addition, Acrivon advances ACR-6840 targeting CDK11. The company uses drug-tailored OncoSignature companion diagnostic tests to match targeted therapies with specific patients likely to respond.
The company operates a certified Clinical Laboratory Improvement Amendments (CLIA) laboratory to process patient samples and perform diagnostic testing in-house. Acrivon is headquartered in Watertown, Massachusetts, where it maintains principal executive offices. The company also conducts operations and leases facility space in Sweden.
Summary of the business section of Acrivon Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Acrivon Therapeutics, Inc.
- Founded
- 2018
- Headquarters
- Watertown, MA
- Address
- 480 Arsenal Way, Suite 100 02472
- Phone
- (617) 207-8979
- Website
- acrivon.com
- Employees
- 74, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ACRV
- Exchange
- Nasdaq
- IPO date
- Nov 16, 2022
- Shares outstanding
- 43M, Aug 7, 2026
- Public float
- $20.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1781174
- CUSIP
- 004890109
- ISIN
- US0048901096
- EIN
- 82-5125532
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kristina Masson | EVP - Business Operations, Director | 2,629,947 |
| Peter Blume-Jensen | President and CEO, Director | 2,615,911 |
| Michaela Levin | Chief Business Officer | 30,000 |
| Eric Devroe | Chief Operating Officer | 146,349 |
| Katharine Peterson | Chief Accounting Officer | 18,033 |
| Erick Gamelin | Chief Development Officer | 52,592 |
| Mary Miller | Chief Legal Officer | 82,009 |
| Adam D. Levy | Chief Financial Officer | 66,008 |
| Mansoor Raza Mirza | Chief Medical Officer | 38,817 |
| Rasmus Holm-Jorgensen | Chief Financial Officer | 26,088 |
| Jean-Marie Cuillerot | Chief Medical Officer | – |
| Santhosh Palani | Director | 9,366 |
| Rajeev M. Shah | Director | – |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | – |
| RA Capital Nexus Fund II, L.P. | Director | 9,366 |
| Charles M. Baum | Director | 9,366 |
| Derek DiRocco | Director | 9,366 |
| Capital Healthcare Fund LP RA | Director | 7,914,206 |
| Sharon Shacham | Director | 9,366 |
| Michael John Tomsicek | Director | 9,366 |
| Ivana Magovcevic-Liebisch | Director | 9,366 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 74 full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 16, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 7, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |